FDA Will Use PET And Biomarkers To Speed Drug Development – Gottlieb
This article was originally published in The Gray Sheet
Executive Summary
FDA's "old-fashioned" regulatory processes have "impeded scientific development" in using assays, biomarkers, genomics and positron emission tomography (PET) to speed drug development, according to FDA Deputy Commissioner for Medical and Scientific Affairs Scott Gottlieb, MD